2. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy1993; 13: 46–59.
3. Lew EA. Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999; 13 (5 suppl): 11–16.
4. Norman A, Hawkey CJ. What you need to know when you prescribe a proton pump inhibitor. Frontline Gastroenterol 2011; 2: 199–205.
5. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739–2754.
6. Horn J. Understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors—focus on pKa and metabolism. Aliment Pharmacol Therapeut Symp 2006; 2: 340–350.
7. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs 2008; 68: 925–947.
8. Kirchheiner J, Glatt S, Fuhr U, et sl. Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65: 19–31.
9. Holt S, Howden CW. Omeprazole. Overview and opinion. Dig Dis Sci 1991; 36: 385–393.
10. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 286–296.
11. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Phys 2007; 76: 1005–1012.
12. Cheatum D, Arvanitakis C, Gumpel M, et sl. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999; 21: 992–1003.
13. Lanza FL, Chan FK, Quigley EM. Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728–738.
14. Yeomans ND, Tulassay Z, Juhasz L, et sl. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719–726.
15. Hawkey CJ, Krrasch AJ, Szczepanski L, et sl. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole vs. Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–734.
16. Chan FK, Wong VW, Suen BY, et sl. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–1626.
17. Gisbert JP, Khorrami S, Carballo F, et sl. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004; 2: CD004062.
18. Ford AC, Delaney BC, Forman D, et sl. Eradication therapy for peptic ulcer disease inHelicobacter pylori positive patients. Cochrane Database Syst Rev 2006; 2: CD003840.
19. Katz PO, Ginsberg GG, Hoyle PE, et sl. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis. Aliment Pharmacol Ther 2007; 25: 617–628.
20. Armstrong D. Gastric pH—the most relevant predictor of benefit in reflux disease. Aliment Pharmacol Ther 2004; 20: 19–26.
21. Triadafilopoulos G. Proton pump inhibitors for Barrett’s oesophagus. Gut 2000; 46: 144–146.
22. Peters FT, Ganesh S, Kuipers EJ, et sl. Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomized double blind study. Gut 1999; 45: 489–494.
23. Horwhat JD, Baroni D, Maydonovitch C, et sl. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2007; 102: 497–508.
24. Charlot M, Ahlehoff O, Norgaard ML, et sl. Proton pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. Ann Intern Med 2010; 153: 378–386.
25. van Boxel OS, van Oijen MG, Hagenaars MP, et sl. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010; 105: 2430–2437.
26. Angiolillo DJ, Gibson CM, Cheng S, et sl. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 69–74.
27. Gremmel T, Steiner S, Seidinger D, et sl. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by five different platelet function tests. J Cardiovasc Pharmacol 2010; 56: 532–539.
28. Bianchi LK, Burke CA, Bennett AE, et sl. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6: 180–185.
29. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23–32.
30. Hodgson N, Koniaris LG, Livingstone AS, et sl. Gastric carcinoids: a temporal increase with proton pump inhibitor introduction. Surg Endosc 2005; 19: 1610–1612.
31. Sandvik AK, Brenna E, Waldum HL, et sl. The pharmacological inhibition of gastric acid secretion—tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013–1018.
32. Waldum HL, Qvigstad G, Fossmark R, et sl. Rebound hypersecretion of acid from a physiological, pathophysiological and clinical point of view. Scand J Gastroenterol 2010; 45: 389–394.
33. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104 (2 suppl): S10–S16.
34. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391–398.
35. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008; 22: 761–766.
36. Gray SL, LaCroix AZ, Larso J, et sl. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med 2010; 170: 765–771.
37. Targownik LE, Lix LM, Metge CJ, et sl. Use of proton pump inhibitors and risk of osteoporotic fractures. CMAJ 2008; 179: 319–326.
38. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313: 70–73.
39. O’Connell MB, Madden DM, Murray AM, et sl. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778–781.
40. Gray SL, LaCroix AZ, Larson J, et sl. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med 2010; 170: 765–771.
41. Yu EW, Blackwell T, Ensrud KE, et sl. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251–259.
42. Targownik LE, Lix LM, Leung S, et sl. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896–904.
43. Food and Drug Administration. Drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). www.fda.gov/drugs/drugsafety/ucm245011.htm
. Published March 2, 2011. Accessed March 8, 2012.
44. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011; 27: 180–185.
45. Falk GW, Fennerty MB, Rothstein RI. AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 2006; 131: 1315–1336.
46. Gaddam S, Wani S, Ahmed H, et sl. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis. Aliment Pharmacol Ther 2010; 32: 1266–1274.
47. Dean BB, Gano AD Jr, Knight K, et sl. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656–664.
48. Lee ES, Kim N, Lee SH, et sl. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther 2009; 30: 154–164.
49. Hiyama T, Matsuo K, Urabe Y, et sl. Meta-analysis used to identify factors associated with effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol2009; 24: 1326–1332.
50. Talley NJ, Axon A, Bytzer P, et sl. Management of uninvestigated and functional dyspepsia: a working party report for the World Congresses of Gastroenterology, 1998. Ailment Pharmacol Ther1999; 13: 1135–1148.
51. Moayyedi P, Delaney BC, Vakil N, et sl. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329–1337.
52. Allescher HD, Bockenhoff A, Knapp G, et sl. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934–941.
53. Khan M, Santana J, Donnellan C, et sl. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; 2: CD003244.
54. Hatlebakk J, Katz P, Kuo B, et sl. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235–1240.
55. Forgacs I. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2–3.
56. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010; 16: e228–e234.
57. Gerson LB, Robbins AS, Garber A, et sl. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395–407.
58. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, et al. (eds): The Pancreas: Biology, Pathobiology and Disease. New York: Raven Press; 1993, 931–978.
59. Corleto VD, Annibale B, Gibril F, et sl. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15: 1555–1561.
60. Ellison EC, Sparks J. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors? Am J Surg 2003; 186: 245–248.